eplivanserin

Eplivanserin is a potent and selective small molecule antagonist of the serotonin 5-HT2A receptor. It was developed as an oral therapy for the treatment of insomnia and other sleep disorders. Unlike older sedating drugs that act on the same receptor class (such as mirtazapine or risperidone), eplivanserin has minimal affinity for dopamine, histamine, or adrenergic receptors. The drug was originally developed by Sanofi Aventis under the planned trade name Ciltyri but its development was discontinued after withdrawal of regulatory applications in both the US and Europe. Eplivanserin also underwent clinical trials for conditions such as chronic pain, fibromyalgia, anxiety disorders, major depressive disorder, apnoea (sleep apnea), and myocardial infarction[1][2][3][4][5][7].

Brand names

CiltyriSliwens

Other names

eplivanserine